Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2GlobeNewsWire • 03/17/21
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsGlobeNewsWire • 03/15/21
Tonix Pharma Shares Rally After In-Licensing Of Technology For A Rare Genetic Eating DisorderBenzinga • 02/11/21
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)GlobeNewsWire • 02/11/21
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital ConferenceGlobeNewsWire • 02/10/21
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 02/09/21
Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 02/08/21
Tonix Pharmaceuticals CEO Believes That Additional COVID-19 Vaccine Research Is Still NeededBenzinga • 02/02/21
Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune ConditionsGlobeNewsWire • 01/14/21
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 01/13/21
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq RulesGlobeNewsWire • 01/11/21
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)GlobeNewsWire • 12/22/20
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human PrimatesGlobeNewsWire • 11/16/20
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development SummitGlobeNewsWire • 11/12/20